The GLP is committed to full transparency. Download and review our Annual Report.

What might be Bayer’s defense if one of the glyphosate cancer verdicts end up at the Supreme Court?

| | May 17, 2019

Bayer AG plans to argue that a $2 billion jury award and thousands of U.S. lawsuits claiming its glyphosate-based weed killer Roundup causes cancer should be tossed because [the U.S. Environmental Protection Agency] said the herbicide is not a public health risk.

Some legal experts believe Bayer will have a tough time convincing appellate courts to throw out verdicts and lawsuits on those grounds. Bayer has a better shot if a business-friendly U.S. Supreme Court takes up the case, experts said. But that could take years.

[T]he company said it will argue that the lawsuits, which are brought under state law, conflict with guidance from …. the EPA [who] reaffirmed prior guidance saying that glyphosate is not a carcinogen ….

Related article:  Glyphosate traces found in wine: Should we be concerned?

Under the legal doctrine of preemption, state law claims are barred if they conflict with federal law …. Lars Noah, a law professor at the University of Florida, said Bayer’s chances of success would increase significantly if the Supreme Court takes up the Roundup appeals.

The high court only accepts around 70 cases each year, but a business-friendly majority on the court could be inclined to hear the dispute ….

Read full, original article: Bayer bets on ‘silver bullet’ defense in Roundup litigation; experts see hurdles

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend